Literature DB >> 1489634

Regional cerebral glucose metabolism in patients with Parkinson's disease with or without dementia.

M Sasaki1, Y Ichiya, S Hosokawa, M Otsuka, Y Kuwabara, T Fukumura, M Kato, I Goto, K Masuda.   

Abstract

By means of positron emission tomography, the cerebral glucose metabolism in 5 patients with Parkinson's disease with dementia was compared with that in 9 patients without dementia, and that in 5 normal volunteers. The metabolic rates for glucose were measured by placing one hundred regions of interest. In the demented patients, cerebral glucose metabolism was diffusely decreased compared with that of the non-demented patients and the normal controls. The most significant decrease in glucose metabolism was observed in the angular gyrus (49.7% of the normal controls). The glucose metabolism in the cingulate, pre- and postcentral, occipital and subcortical regions was relatively spared (62.1 to 85.5% of the normal controls). In the patients without dementia, the glucose metabolism in each region was not significantly different from that in the normal controls. These results suggest that diffuse glucose hypometabolism in the cerebral cortex may correlate with that of patients with Parkinson's disease with dementia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489634     DOI: 10.1007/bf03164661

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  14 in total

1.  Cortical glucose metabolism in Parkinson's and Alzheimer's disease.

Authors:  R F Peppard; W R Martin; C M Clark; G D Carr; P L McGeer; D B Calne
Journal:  J Neurosci Res       Date:  1990-12       Impact factor: 4.164

Review 2.  Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review.

Authors:  S I Rapoport
Journal:  Cerebrovasc Brain Metab Rev       Date:  1991

3.  Alternative formula for glucose utilization using labeled deoxyglucose.

Authors:  R A Brooks
Journal:  J Nucl Med       Date:  1982-06       Impact factor: 10.057

4.  Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method.

Authors:  D E Kuhl; E J Metter; W H Riege
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

5.  Dementia in Parkinson disease: a neuropathologic study.

Authors:  A M Hakim; G Mathieson
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

6.  The 'subcortical dementia' of progressive supranuclear palsy.

Authors:  M L Albert; R G Feldman; A L Willis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-02       Impact factor: 10.154

7.  The synthesis of 2-[F-18]fluoro-2-deoxy-D-glucose using glycals: a reexamination.

Authors:  G T Bida; N Satyamurthy; J R Barrio
Journal:  J Nucl Med       Date:  1984-12       Impact factor: 10.057

8.  How common is dementia in Parkinson's disease?

Authors:  R G Brown; C D Marsden
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

9.  Dementia in Parkinson Disease.

Authors:  A Lieberman; M Dziatolowski; M Kupersmith; M Serby; A Goodgold; J Korein; M Goldstein
Journal:  Ann Neurol       Date:  1979-10       Impact factor: 10.422

10.  [Comparison study of positron emission tomography, X-ray CT and MRI in parkinsonism with dementia].

Authors:  J Okada; R Peppard; D B Calne
Journal:  Nihon Igaku Hoshasen Gakkai Zasshi       Date:  1989-05-25
View more
  4 in total

1.  Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.

Authors:  Paul Edison; Imtiaz Ahmed; Zhen Fan; Rainer Hinz; Giorgio Gelosa; K Ray Chaudhuri; Zuzana Walker; Federico E Turkheimer; David J Brooks
Journal:  Neuropsychopharmacology       Date:  2012-12-06       Impact factor: 7.853

2.  Three-dimensional surface display of brain perfusion with 123I-IMP in Parkinson's disease.

Authors:  H Tachibana; K Kawabata; Y Tomino; M Sugita; M Fukuchi
Journal:  Neuroradiology       Date:  1994-05       Impact factor: 2.804

Review 3.  Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease.

Authors:  George E Barreto; Alexander Iarkov; Valentina Echeverria Moran
Journal:  Front Aging Neurosci       Date:  2015-01-09       Impact factor: 5.750

Review 4.  Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Authors:  Zuzana Walker; Federica Gandolfo; Stefania Orini; Valentina Garibotto; Federica Agosta; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Marina Boccardi; Daniele Altomare; Cristina Festari; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-19       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.